55559-72-3

Basic information

• Product Name: (2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol
• Synonyms: 1,2-propanediol, 3-(6-amino-9H-purin-9-yl)-, (2R)-
• CAS NO: 55559-72-3
• Molecular Formula: C₈H₁₁N₅O₂
• Molecular Weight: 209.2052
• Mol File: 55559-72-3.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 577.8°C at 760 mmHg
• Flash Point: 303.2°C
• Density: 1.73g/cm³
• Vapor Pressure: 3.43E-14mmHg at 25°C
• Refractive Index: 1.788
• CAS DataBase Reference: (2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol(55559-72-3)
• EPA Substance Registry System: (2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol(55559-72-3)

Safety Data

• Hazardous Substances Data: 55559-72-3(Hazardous Substances Data)

Usage

General Description

(2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol is a chemical compound that consists of a purine base attached to a propane-1,2-diol molecule. The purine base contains an amino group and is commonly found in nucleic acids such as DNA and RNA. The propane-1,2-diol molecule, also known as glycerol, is a simple sugar alcohol that is commonly used as a solvent, sweetener, and preservative in the food and pharmaceutical industries. (2R)-3-(6-amino-9H-purin-9-yl)propane-1,2-diol may have potential applications in medicine and biochemistry due to its purine and glycerol components, which are essential for many biological processes. Additionally, it may have potential uses in the development of drugs and therapeutic compounds due to its structural features.

Upstream product

• 4704-77-2 1-bromo-2,3-propanediol 
• 66224-66-6 adenine 
• 4121-39-5 9-allyl-9H-adenine 
• 1638138-13-2 9-(((R)-2,2-cyclohexylidine-1,3-dioxolan-4-yl)methyl)-9H-purin-6-amine 
• 55569-49-8 (D)-9-(α,β-1-methyl-5-ribofuranosyl)adenine 
• 724440-92-0 (R)-3-(6-Amino-purin-9-yl)-2-(2-hydroxy-1-methoxy-ethoxy)-propan-1-ol 
• 23485-30-5 N⁹-(2,2-diethoxyethyl)adenine 
• 94535-32-7 (RS)-3-(Adenin-9-yl)-2-hydroxypropanoic Acid 
• 33841-98-4 2-(6-amino-9H-purin-9-yl)acetaldehyde 
• 556-52-5 oxiranyl-methanol 
• 76512-99-7 N⁶-formyl-9-(2,3-dihydroxypropyl)adenine 
• 94535-30-5 Methyl (RS)-3-(Adenin-9-yl)-2-hydroxypropanoate 
• 69369-04-6 9-(RS)-(2,3-dihydroxypropyl)-8-bromoadenine 

Downstream Products

• 81546-79-4 9-((RS)-3-p-toluenesulfonyloxy-2-(tetrahydropyran-2-yloxy)propyl)adenine 
• 87888-92-4 C₂₂H₂₃N₅O₇S₂ 
• 87888-91-3 Toluene-4-sulfonic acid 3-(6-amino-8-hydroxy-purin-9-yl)-2-hydroxy-propyl ester 
• 123156-39-8 [2-(6-Benzoylamino-purin-9-yl)-1-hydroxy-ethyl]-phosphonic acid diethyl ester 
• 87888-88-8 8-Benzyloxy-9-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-9H-purin-6-ylamine 
• 123156-36-5 2-(N⁶-benzoyladenin-9-yl)ethanal 
• 85446-34-0 9-(RS)-(2,3-dihydroxypropyl)-6-hydroxylaminopurine 
• 115233-96-0 N⁶-benzoyl-9-(R)-(2-hydroxy-3-triphenylmethoxypropyl)adenine 
• 115233-91-5 N⁶-benzoyl-9-(R)-(2,3-dihydroxypropyl)adenine 
• 148873-43-2 N⁶,N⁶-dibenzoyl-9-(R)-(2,2-dimethyl-1,3-dioxolan-4-ylmethyl)adenine 
• 115196-79-7 N⁶-benzoyl-9-(R)-(2,2-dimethyl-1,3-dioxolan-4-ylmethyl)adenine 

Relevant articles and documents

Synthesis of Chiral Acyclic Nucleosides by Sharpless Asymmetric Dihydroxylation: Access to Cidofovir and Buciclovir

An efficient method to construct chiral acyclic nucleosides via Sharpless asymmetric dihydroxylation of N-allylpyrimidines or N-alkenylpurines is reported. A range of chiral acyclic nucleosides with two adjacent hydroxyl groups present on the side chains could be produced in good yields (up to 97% yield) and excellent enantioselectivities (90-99% ee). The synthetic utility of the reaction was demonstrated by the catalytic asymmetric synthesis of (S)-Cidofovir and (R)-Buciclovir.

8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands

Importance of making available selective adenosine receptor antagonists is boosted by recent findings of adenosine involvement in many CNS dysfunctions. In the present work a series of 8-bromo-9-alkyl adenines are prepared and fully characterized in radio

Enantiomeric radiochemical synthesis of R and S (1-(6-amino-9H-purin-9-yl)- 3-fluoropropan-2-yloxy)methylphosphonic acid (FPMPA)

Therapy for human immunodeficiency virus (HIV)-infected patients requires chronic multidrug administration. The eventual failure of therapy in some patients has brought into question the tissue concentration of the drugs. With an appropriately radiolabele